María
Díez Campelo
Profesora Asociada CC. Salud
![Foto de María](/img/uploaded/38c5a6a747cb7a6f7166f9e46294ab84.jpg)
![Foto de University Medical Center Freiburg](/img/noimage_org.png)
University Medical Center Freiburg
Friburgo de Brisgovia, AlemaniaPublicacións en colaboración con investigadores/as de University Medical Center Freiburg (3)
2022
-
MDS-110 SELECT-MDS-1 Trial in Progress: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tamibarotene/Azacitidine Versus Placebo/Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk MDS
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S303-S304
2021
-
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
Leukemia, Vol. 35, Núm. 3, pp. 835-849
-
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Leukemia, Vol. 35, Núm. 6, pp. 1745-1750